慢性肾脏病患者的血脂、载脂蛋白与动脉粥样硬化性心血管疾病风险
本研究基于美国CRIC前瞻性队列中3811例非透析依赖性CKD成人,随访中位7.9年,评估基线血脂和载脂蛋白三分位与ASCVD复合终点(心梗或缺血性卒中)的关联。结果显示VLDL-C最高三分位、Apo-B中间三分位、HDL-C中间和最低三分位、Apo-AI中间和最低三分位与ASCVD风险升高相关,而LDL-C最高三分位无显著关联。
要点
- VLDL-C最高三分位者ASCVD风险升高(HR 1.28,95%CI 1.01-1.64)。
- HDL-C最低三分位者ASCVD风险升高(HR 1.77,95%CI 1.35-2.33)。
- LDL-C最高三分位与ASCVD风险无显著关联(HR 1.00,95%CI 0.77-1.30)。
核心结论
- 在非透析依赖性CKD成人中,较高的VLDL-C和Apo-B水平以及较低的HDL-C和Apo-AI水平与ASCVD风险升高相关。
- LDL-C水平与ASCVD风险无显著关联。
- 研究结果支持未来探索针对LDL-C以外的脂蛋白(如富含甘油三酯的脂蛋白)以降低CKD患者残余ASCVD风险。
研究设计与样本
- 前瞻性队列研究,纳入美国7个临床中心的CRIC研究中的3811例21至74岁非透析依赖性CKD成人。
- 基线血脂和载脂蛋白水平按三分位分层,随访中位7.9年。
- 采用多变量Cox比例风险回归估计各三分位的ASCVD风险。
主要发现
- 随访期间共发生451例ASCVD事件(心梗或缺血性卒中复合终点)。
- VLDL-C最高三分位与ASCVD风险升高相关(HR 1.28;95%CI 1.01-1.64)。
- Apo-B中间三分位与ASCVD风险升高相关(HR 1.30;95%CI 1.03-1.64)。
- HDL-C中间和最低三分位与ASCVD风险升高相关(HR分别为1.40 [95%CI 1.08-1.83]和1.77 [95%CI 1.35-2.33])。
- Apo-AI中间和最低三分位与ASCVD风险升高相关(HR分别为1.77 [95%CI 1.02-1.74]和1.77 [95%CI 1.36-2.32])。
关键数值与推荐
- VLDL-C最高三分位:HR 1.28(95%CI 1.01-1.64)。
- Apo-B中间三分位:HR 1.30(95%CI 1.03-1.64)。
- HDL-C中间三分位:HR 1.40(95%CI 1.08-1.83);最低三分位:HR 1.77(95%CI 1.35-2.33)。
- Apo-AI中间三分位:HR 1.77(95%CI 1.02-1.74);最低三分位:HR 1.77(95%CI 1.36-2.32)。
- LDL-C最高三分位:HR 1.00(95%CI 0.77-1.30)。
临床怎么用
- 在CKD患者ASCVD风险评估中,可关注VLDL-C、Apo-B、HDL-C和Apo-AI水平,而非仅依赖LDL-C。
- 对于LDL-C达标但存在高VLDL-C或Apo-B、低HDL-C或Apo-AI的CKD患者,残余ASCVD风险可能仍较高。
- 研究提示未来可探索针对富含甘油三酯脂蛋白的干预以降低CKD患者残余ASCVD风险。
局限性
- 基于观察性数据的关联不能推断因果关系。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: A large residual risk for atherosclerotic cardiovascular disease (ASCVD) remains in the setting of chronic kidney disease (CKD) despite treatment with statins. We sought to evaluate the associations of lipid and apolipoprotein levels with risk for ASCVD in individuals with CKD. STUDY DESIGN: Prospective cohort study. SETTINGS & PARTICIPANTS: Adults aged 21 to 74 years with non-dialysis-dependent CKD at baseline enrolled in the Chronic Renal Insufficiency Cohort (CRIC) Study in 7 clinical study centers in the United States. PREDICTOR: Baseline total cholesterol, non-high-density lipoprotein cholesterol (non-HDL-C), very low-density lipoprotein cholesterol (VLDL-C), triglycerides, low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo-B), HDL-C, and apolipoprotein AI (Apo-AI) values stratified into tertiles. OUTCOME: A composite ASCVD event of myocardial infarction or ischemic stroke. ANALYTIC APPROACH: Multivariable Cox proportional hazards regression to estimate the risk for ASCVD for each tertile of lipoprotein predictor. RESULTS: Among 3,811 CRIC participants (mean age, 57.7 years; 41.8% white), there were 451 ASCVD events during a median follow-up of 7.9 years. There was increased ASCVD risk among participants with VLDL-C levels in the highest tertile (HR, 1.28; 95% CI, 1.01-1.64), Apo-B levels in the middle tertile (HR, 1.30; 95% CI, 1.03-1.64), HDL-C levels in the middle and lowest tertiles (HRs of 1.40 [95% CI, 1.08-1.83] and 1.77 [95% CI, 1.35-2.33], respectively), and Apo-AI levels in the middle and lowest tertiles (HRs of 1.77 [95% CI, 1.02-1.74] and 1.77 [95% CI, 1.36-2.32], respectively). LDL-C level was not significantly associated with the ASCVD outcome in this population (HR, 1.00 [95% CI, 0.77-1.30] for the highest tertile). LIMITATIONS: Associations based on observational data do not permit inferences about causal associations. CONCLUSIONS: Higher VLDL-C and Apo-B levels, as well as lower HDL-C and Apo-AI levels, are associated with increased risk for ASCVD. These findings support future investigations into pharmacologic targeting of lipoproteins beyond LDL-C, such as triglyceride-rich lipoproteins, to reduce residual risk for ASCVD among individuals with CKD.
引用
- Bajaj A, Xie D, Cedillo-Couvert E, et al. Lipids, Apolipoproteins, and Risk of Atherosclerotic Cardiovascular Disease in Persons With CKD. Am J Kidney Dis. 2019. PMID: 30686529. doi:10.1053/j.ajkd.2018.11.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。